Intraoperative Radiotherapy (IORT) with Low-Energy Photons as a Boost in Patients with Early-Stage Oral Cancer with the Indications for Postoperative Radiotherapy

被引:0
|
作者
Rutkowski, Tomasz [1 ,2 ]
Wygoda, Andrzej [1 ,2 ]
Hutnik, Marcin [1 ,2 ]
Skladowski, Krzysztof [1 ,2 ]
Wydmanski, Jerzy [1 ,2 ]
Maciejewski, Adam [2 ,3 ]
Szymczyk, Cezary [2 ,3 ]
Wierzgon, Janusz [2 ,3 ]
Orlef, Andrzej [2 ,4 ]
Maciejewski, Boguslaw [1 ,2 ]
机构
[1] Maria Sklodowska Curie Mem Canc Ctr, Dept Radiat Oncol, PL-44100 Gliwice, Poland
[2] Inst Oncol, Gliwice Branch, PL-44100 Gliwice, Poland
[3] Maria Sklodowska Curie Mem Canc Ctr, Dept Surg, PL-44100 Gliwice, Poland
[4] Maria Sklodowska Curie Mem Canc Ctr, Dept Phys, PL-44100 Gliwice, Poland
关键词
Oral cancer; Intraoperative radiotherapy; Photon Radiosurgery System; Head and neck cancer; Boost; SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; RESECTION MARGIN; ADVANCED HEAD; BRAIN-TUMORS; NECK-CANCER; X-RAYS; RECURRENT; TONGUE; MANAGEMENT;
D O I
10.1007/s00066-010-2117-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the feasibility and preliminary results of intraoperative radiotherapy (TORT) with low-energy photons as a boost in patients with early-stage oral cancer with the indications for postoperative radiotherapy. Patients and Methods: Between 2003 and 2006, 16 patients with early-stage cancer of mobile tongue (n = 10 [63%]) or floor of the mouth (n = 6 [37%]) treated at Maria Sktodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland, were evaluated for IORT boost with the INTRABEAM (R) System (Carl Zeiss Surgical GmbH; IORT-PRS) because of the high risk of local recurrence due to positive margins on frozen pathologic section. After tumor resection, the applicator was positioned in the tumor bed. The applicator's diameter (range: 1.5-5 cm) was selected to encompass high-risk area of tumor recurrence. The dose (5 Gy, 7 Gy, or 7.5 Gy) was applied according to tumor volume and bone proximity. External-beam radiotherapy (EBRT) was provided to the tumor bed in all patients (50 Gy) and to the nodal area, when needed. Toxicity and local tumor control were assessed. Results: Median follow-up was 36 months. TORT did not increase acute mucosal reaction. Local tumor control was found in all cases. Early mucosal reaction did not exceed 3 according to the RTOG scale and healed in median time of 35 days after completion of EBRT. No late adverse effects were observed. Conclusion: This preliminary report has demonstrated the feasibility of IORT-PRS for patients with early oral cancer with the indications for postoperative radiotherapy. This method may be considered an alternative boost technique, although additional studies are needed to establish long-term results in a larger group of patients.
引用
收藏
页码:496 / 501
页数:6
相关论文
共 50 条
  • [31] Application of Intraoperative Radiotherapy in Early-Stage Breast Cancer Patients in a Clinical Setting
    Wang, Ao
    Quint, Elchanan
    Kukeev, Ivan
    Agassi, Ravit
    Belochitski, Olga
    Barski, Gay
    Vaynshtein, Julie
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2024, 2024
  • [32] INTRAOPERATIVE RADIOTHERAPY (IORT) AS A BOOST DURING CONSERVING SURGERY IN WOMEN WITH EARLY BREAST CANCER.
    Warenczak-Florczak, Z.
    Bratos, K.
    Wlodarczyk, H.
    Roszak, A.
    Murawa, D.
    Karczewska-Dzionk, A.
    Milecki, P.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S7 - S7
  • [33] Intraoperative Radiotherapy (IORT) in patients with recurrent rectal cancer
    Roeder, F.
    Goetz, J. M.
    Timke, C.
    Krause, S.
    Hensley, F. W.
    Bischof, M.
    Weitz, J.
    Buechler, M. W.
    Debus, J.
    Krempien, R.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2009, 185 : 108 - 108
  • [34] Hypofractionated Whole Breast Radiotherapy and Boost in Early-Stage Breast Cancer
    Gary M. Freedman
    Neil K. Taunk
    Current Breast Cancer Reports, 2020, 12 : 296 - 304
  • [35] Intraoperative radiotherapy (IORT) of early breast cancer with low-energy x-rays in breast-conserving surgeryProspective identification of pre- and intraoperative factors influencing the feasibility of IORT
    Anja Grimm
    Eva Wollmann
    Elena Sperk
    Christel Weiß
    Marc Sütterlin
    Sebastian Berlit
    Benjamin Tuschy
    Strahlentherapie und Onkologie, 2024, 200 : 296 - 305
  • [36] Hypofractionated Whole Breast Radiotherapy and Boost in Early-Stage Breast Cancer
    Freedman, Gary M.
    Taunk, Neil K.
    CURRENT BREAST CANCER REPORTS, 2020, 12 (04) : 296 - 304
  • [37] Intraoperative Radiotherapy of the Breast for Early-Stage Breast Cancer: Ready for Primetime
    Holmes, Dennis R.
    BREAST JOURNAL, 2015, 21 (02): : 181 - 184
  • [38] A prospective phase I comparison of toxicity and cosmesis outcomes of single-fraction IORT and hypofractionated radiotherapy with IORT boost in early-stage breast cancer
    Bhandari, Tanuja
    Babaran, Wesley
    Forouzannia, Afshin
    Williams, Venita
    Harness, Jay
    Carpenter, Michele
    Gobran, Maher
    Khanijou, Rajesh
    Wagman, Brittany
    Ash, Robert
    Wagman, Lawrence D.
    BRACHYTHERAPY, 2017, 16 (06) : 1232 - 1238
  • [39] Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?
    Fodor, Andrei
    Brombin, Chiara
    Mangili, Paola
    Borroni, Fulvio
    Pasetti, Marcella
    Tummineri, Roberta
    Zerbetto, Flavia
    Longobardi, Barbara
    Perna, Lucia
    Dell'Oca, Italo
    Deantoni, Chiara L.
    Deli, Aniko M.
    Chiara, Anna
    Broggi, Sara
    Castriconi, Roberta
    Esposito, Pier Giorgio
    Slim, Najla
    Passoni, Paolo
    Baroni, Simone
    Villa, Stefano L.
    Rancoita, Paola M., V
    Fiorino, Claudio
    Del Vecchio, Antonella
    Bianchini, Giampaolo
    Gentilini, Oreste D.
    Di Serio, Mariaclelia S.
    Di Muzio, N. G.
    BREAST, 2021, 55 : 45 - 54
  • [40] Early initiation of External Beam Radiotherapy (EBRT) increases the risk of long term toxicity in patients undergoing Intraoperative Radiotherapy (IORT) as a boost for breast cancer
    Blank, E.
    Welzel, G.
    Keller, A.
    Vorodi, F.
    Herskind, C.
    Scheda, A.
    Tome, O.
    Suetterlin, M.
    Kraus-Tiefenbacher, U.
    Wenz, F.
    ONKOLOGIE, 2008, 31 : 52 - 52